Cargando…
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
BACKGROUND: In clinical practice, different antipsychotics can be combined in the treatment of people with schizophrenia (polypharmacy). This strategy can aim at increasing efficacy, but might also increase the adverse effects due to drug–drug interactions. Reducing polypharmacy by withdrawing one o...
Autores principales: | Bighelli, Irene, Rodolico, Alessandro, Siafis, Spyridon, Samara, Myrto T, Hansen, Wulf-Peter, Salomone, Salvatore, Aguglia, Eugenio, Cutrufelli, Pierfelice, Bauer, Ingrid, Baeckers, Lio, Leucht, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427025/ https://www.ncbi.nlm.nih.gov/pubmed/36042158 http://dx.doi.org/10.1002/14651858.CD014383.pub2 |
Ejemplares similares
-
Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
por: Rodolico, Alessandro, et al.
Publicado: (2022) -
S204. REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS
por: Leucht, Stefan, et al.
Publicado: (2020) -
Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in an Italian Sample of Patients with Stable Schizophrenia and Bipolar Spectrum Disorders
por: Rodolico, Alessandro, et al.
Publicado: (2022) -
Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008) -
Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
por: Kamei, Hiroyuki
Publicado: (2022)